FMP
Diffusion Pharmaceuticals Inc.
DFFN
NASDAQ
Inactive Equity
Diffusion Pharmaceuticals Inc., a biopharmaceutical company, develops novel therapies that enhance the body's ability to deliver oxygen. Its lead product candidate is Trans Sodium Crocetinate that is developed to enhance the diffusion of oxygen to tissues, as well as to treat COVID-19 disease. Diffusion Pharmaceuticals Inc. was founded in 2001 and is based in Charlottesville, Virginia.
4.4 USD
0.41 (9.32%)
It looks like there's no news available.